We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
BofA on Aurobindo Pharma: Buy| Target Rs 650
BofA Securities maintained its buy rating on Aurobindo Pharma with a target price of Rs 650. “Positive traction is seen in the US GX which is driving the beat,” the investment bank said.
“Growth drivers to unfold in FY24-25. The US recovery in Q3 with more to come. The medium-term growth levers are likely to play out from H2FY24,” it added.
JPMorgan on M&M: Overweight | Target Rs 1520
JPMorgan maintained its overweight rating on M&M with a target price of Rs 1520 post Q3 results.
“Q3 results were ‘Steady as she goes’. Auto + Farm EBIT was in line with estimates,” said the note. “The auto segment margins were surprisingly positive,” it added.“We remain encouraged by M&M’s consolidated ROE improvement. FY24-25E estimates are largely unchanged,” the note added.
Morgan Stanley on PolicyBazaar: Overweight| Target Rs 705
Morgan Stanley maintained its overweight stance on
with a target price of Rs 705. “The company reported a good set of numbers for Q3. It is among the preferred plays in the insurance sector,” said the note.
The global investment bank expects PBFI to do better than its guidance on profitability. “The stock has been absorbing post-IPO lockup supply well, and the valuation remains attractive,” it added.
Morgan Stanley on Delhivery: Overweight| Target Rs 370
Morgan Stanley maintained its overweight stance on Delhivery with a target price of Rs 370.
“Operating leverage is high. Cost rationalization resulted in better-than-expected adjusted EBITDA. However, the revenue growth is missing estimates,” it said.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.